The University of Wisconsin Madison has a long and rich history as an international leader in basic, translational and clinical cancer research. Its history reflects the development of two NCI designated cancer research centers founded by Dr. Harold Rusch on the campus of UW Madison. The McArdle Laboratory for Cancer Research was founded in 1940 and the University of Wisconsin Comprehensive Cancer Center was awarded NCI funding as one of the first comprehensive cancer centers in 1973. Today the University of Wisconsin Comprehensive Cancer Center is comprised of 253 members from 52 departments and 9 schools of the University of Wisconsin Madison. The organizational structure that brings together this diverse community of investigators is centered around seven scientific research programs and fifteen Disease Oriented Working Groups. Together the members receive $105M in direct cost funding for cancer related research, $89M is peer-reviewed. $28M is from NCI, $51M from other NIH Institutes, and $10M from other peer-reviewed sources. The three highest goals of the UWCCC, now and for the future, are: 1) to conduct the highest quality research into the origins and control of cancer; 2) to translate these research findings to evaluation in the clinic through well designed clinical trials with corresponding biologic endpoints whenever possible;and 3) to provide the best care possible to all cancer patients by carefully integrating high quality cutting edge care with clinical research in a compassionate and individualized manner. To address these goals during the next grant period, UWCCC priorities for future development will be: * Strengthening of programmatic cancer focused intra- and transdisciplinary basic and clinical research capabilities especially in Aging and Cancer and in Immunology * Focus research on health disparities and the delivery of outstanding cancer care to all populations * Enhancement of research infrastructure by further development of shared resources * Completion of clinical and research facility remodeling and expansions

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014520-37S2
Application #
8144098
Study Section
Subcommittee G - Education (NCI)
Program Officer
Vanduyn, Maryann
Project Start
1976-01-01
Project End
2012-03-31
Budget Start
2010-04-29
Budget End
2011-03-31
Support Year
37
Fiscal Year
2010
Total Cost
$148,912
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Schumacher, Jessica R; Neuman, Heather B; Chang, George J et al. (2018) A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01). Ann Surg Oncol 25:2587-2595
Turk, Anita A; Wisinski, Kari B (2018) PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer 124:2498-2506
Liu, Ting; Shi, Changzheng; Duan, Linqi et al. (2018) A highly hemocompatible erythrocyte membrane-coated ultrasmall selenium nanosystem for simultaneous cancer radiosensitization and precise antiangiogenesis. J Mater Chem B 6:4756-4764
Zhan, Yonghua; Ehlerding, Emily B; Shi, Sixiang et al. (2018) Intrinsically Zirconium-89-Labeled Manganese Oxide Nanoparticles for In Vivo Dual-Modality Positron Emission Tomography and Magnetic Resonance Imaging. J Biomed Nanotechnol 14:900-909
Bloom, Debra D; Reshetylo, Sofiya; Nytes, Cassandra et al. (2018) Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity. J Immunother 41:213-223
Wei, Weijun; Jiang, Dawei; Ehlerding, Emily B et al. (2018) Noninvasive PET Imaging of T cells. Trends Cancer 4:359-373
Fricke, Stephanie L; Payne, Susan N; Favreau, Peter F et al. (2018) MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers. Mol Cancer Ther :
Feld, Shara I; Fan, Jun; Yuan, Ming et al. (2018) Utility of Genetic Testing in Addition to Mammography for Determining Risk of Breast Cancer Depends on Patient Age. AMIA Jt Summits Transl Sci Proc 2017:81-90
Hernández-Santos, Nydiaris; Wiesner, Darin L; Fites, J Scott et al. (2018) Lung Epithelial Cells Coordinate Innate Lymphocytes and Immunity against Pulmonary Fungal Infection. Cell Host Microbe 23:511-522.e5
van Ravesteyn, Nicolien T; van den Broek, Jeroen J; Li, Xiaoxue et al. (2018) Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches. Med Decis Making 38:126S-139S

Showing the most recent 10 out of 1528 publications